

1 **Salivary DNA loads for human herpes viruses 6 and 7 are correlated with disease**
2 **phenotype in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome**

3

4 **Ji-Sook Lee¹, Eliana M. Lacerda², Luis Nacul², Caroline C. Kingdon², Jasmin Norris², Shennae**
5 **O'Boyle², Chrissy H. Roberts², Luigi Palla², Eleanor M. Riley^{1,2#}, Jacqueline M. Cliff^{1,*}**

6

7 ¹Department of Infection Biology and ²Clinical Research Department, Faculty of Infectious and
8 Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom

9 [#]Institute of Immunology and Infection Research, School of Biological Sciences, University of
10 Edinburgh, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK

11

12 *** Correspondence:**

13 Dr Jacqueline Cliff

14 jackie.cliff@lshtm.ac.uk

15 **Keywords: ME/CFS, Human Herpesvirus, DNA viral load, clinical specimens, digital droplet**
16 **PCR (Min.5-Max. 8)**

17

18 **Abstract**

19 Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) is a complex chronic
20 condition affecting multiple body systems, with unknown cause, unclear pathogenesis mechanisms,
21 and fluctuating symptoms which may lead to severe debilitation. It is frequently reported to have
22 been triggered by an infection, particularly with herpes virus family members; however, there are no
23 clear differences in exposure to, or seroprevalence of, any herpes virus in people with ME/CFS and
24 healthy individuals. Herpes viruses exist in lytic and latent forms, and it is possible that ME/CFS is
25 associated with viral reactivation, which has not been detectable previously due to insensitive testing
26 methods.

27 Saliva samples were collected from 30 people living with ME/CFS at monthly intervals for
28 six months and at times when they experienced symptom exacerbation, as well as from 14 healthy
29 control individuals. The viral DNA load of the nine human herpes viruses was determined by digital
30 droplet PCR. Symptoms were assessed by questionnaire at each time point.

31 Human herpes virus (HHV) 6B, HHV-7, herpes simplex virus 1 and Epstein Barr virus were
32 detectable within the saliva samples, with higher HHV-6B and HHV-7 viral loads detected in people
33 with ME/CFS than in healthy controls. Participants with ME/CFS could be broadly separated into
34 two groups: one group displayed fluctuating patterns of herpes viruses detectable across the six
35 months while the second group displayed more stable viral presentation. In the first group, there was
36 positive correlation between HHV-6B and HHV-7 viral load and severity of symptom scores,
37 including pain, neurocognition and autonomic dysfunction.

38 The results indicate that fluctuating viral load, related to herpesvirus reactivation state, may
39 play a role in ME/CFS pathogenesis, or might be a consequence of dysregulated immune function.
40 The sampling strategy and molecular tools developed permit large-scale epidemiological
41 investigations.

42 **Contribution to the Field**

43 The cause of ME/CFS and the mechanisms underlying disease pathogenesis are not known, although
44 symptoms are often triggered by infection. Human herpes virus (HHV) family members have been
45 implicated, although there is no difference in the seroprevalence of any HHV in people with ME/CFS
46 and healthy controls, showing there is similar prior infection rate. HHVs exist in either latent or
47 active, lytic, phases in the human host, and it is possible that ME/CFS symptoms and their severity is
48 related to HHV reactivation from a latent state. We have used droplet digital PCR, a sensitive and
49 specific method, to measure the prevalence and DNA concentration of HHVs in the saliva of people
50 with ME/CFS and controls, and analysed the correlation with disease over a six-month timecourse.
51 We found that two HHVs, HHV-7 and HHV-6B, were elevated in saliva from people with ME/CFS,
52 and that in people who were severely affected by ME/CFS, the concentration HHV DNA correlated
53 with symptom severity over time in a subgroup of patients with fluctuating salivary HHV repertoire.
54 Our study demonstrates the feasibility of measuring HHV concentration in readily acquired samples,
55 enabling future large-scale studies aimed at testing the causal role of HHV reactivation in ME/CFS
56 disease.

57

58 **1. Introduction**

59 Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown
60 aetiology, causing persistent or recurrent incapacitating fatigue; a hallmark symptom is post-
61 exertional malaise (PEM). Other symptoms, which are present to a varying degree in different
62 individuals, include pain and disturbances in immune function along with lymphadenopathy,
63 unrefreshing sleep, cognitive difficulties, and dysfunction of the endocrine and autonomic nervous
64 systems [1, 2]. Despite a prevalence in Europe ranging from 0.1% to 2.2% [3], there is still no
65 diagnostic test for ME/CFS, hampering research into its cause and pathogenesis, and development of
66 treatments. While the risk of developing ME/CFS is likely to be multifactorial, in approximately 50%
67 of cases ME/CFS symptoms appear after a “viral-like” illness, and it is possible that an infectious
68 disease can trigger ME/CFS onset. However, no single causative pathogen has been identified for
69 ME/CFS, despite extensive research [4].

70 Although there have been reports that bacterial infections such as Lyme disease [5] or Q fever
71 [6] can trigger ME/CFS, it is mostly commonly viral infections, especially those from the herpes
72 virus family, which have been more widely associated with ME/CFS [4]. There are nine members of
73 the human herpes virus (HHV) family which naturally infect humans: herpes simplex virus-1 and -2
74 (HSV-1, HSV-2), varicella-zoster virus (VZV), which is the causative agent of chicken pox and
75 shingles, Epstein-Barr virus (EBV), which causes infectious mononucleosis, human
76 cytomegalovirus (HCMV), HHV6 including subtypes HHV6A and HHV6B, HHV7 and Kaposi’s
77 sarcoma virus (KSHV). These viruses are all of potential interest in ME/CFS due to their ability to
78 latently infect either neurons or immune system cells, both of which may be affected in ME/CFS.
79 There has been speculation that Epstein Barr Virus (EBV) is involved in ME/CFS pathogenesis for
80 many years [7, 8], although reports are inconsistent [9, 10]. Reports of the potential involvement of

81 CMV in ME/CFS are also mixed, with higher anti-CMV antibodies reported in serum in ME/CFS
82 compared to healthy controls (HCs) in one study [11] but no correlation in another [12]. HHV-6 and
83 HHV-7, which are from the *Roseolovirus* genus of the *Beta-herpesvirinae* subfamily, cause
84 widespread long-term persistent infection with reported population prevalence of >90% [13] with
85 infection usually occurring within the first three years of life. In early studies, there was serological
86 indication of HHV-6 reactivation with higher specific anti-HHV-6 serum antibody concentration in
87 people living with ME/CFS than in HCs [14, 15] but these data have been contradicted in other
88 studies [16]. Similarly, HHV-7 infection is commonly detectable in people living with ME/CFS, but
89 the detection rate of HHV-7 DNA is similar in ME/CFS patients and in HCs [17].

90 Thus, reports of association between herpes virus infection and ME/CFS are inconsistent.
91 This may be due partly to small sample sizes in some studies, and to heterogeneity within and
92 between ME/CFS populations included in different studies. We did not find any difference in
93 seroprevalence or antibody titres against the eight herpes viruses between people living with
94 ME/CFS and HCs in our previous work [18]. However, a hallmark feature of herpes viruses is their
95 life cycle in which, following an acute infection, they remain in the host in a latent persistent form,
96 and can reactivate following immune system disturbance. Measurements of antibody titre by ELISA
97 and qPCR analysis of viral DNA concentration in blood may be too insensitive to fully distinguish
98 reactivation events from latent infection, and a more sensitive analysis might enable the full
99 characterisation of herpes virus reactivation events in ME/CFS, leading to a definitive answer
100 regarding the role of herpes virus infections in this condition. Digital droplet PCR (ddPCR) permits
101 absolute quantification of nucleic acids [19]. This is achieved via an emulsion process in which the
102 fluorescent probe-based PCR reaction is partitioned into approximately 15,000 highly uniform, one
103 nanolitre volume, reverse (water-in-oil) micelles that are stable at high temperatures: each droplet is
104 essentially an independent nano-PCR. Enumeration of the number of positive and negative droplets
105 post-PCR gives a sensitive and precise readout of the template DNA concentration.

106 In this study, we hypothesised that ME/CFS may follow an acute infection with a herpes
107 virus, with symptoms being triggered by a virus reactivation, followed by a state of “aberrant
108 homeostasis” [20]. Although these viral infections are common, it is possible that people living with
109 ME/CFS experience prolonged or more frequent reactivation events than healthy individuals and are
110 unable to consistently contain a latent infection. We aimed to develop highly sensitive and specific
111 ddPCR assays for the human herpes family viruses, and use them to test for correlation between viral
112 load in saliva, an accessible sample likely to be involved in transmission [16], and the clinical
113 manifestations of disease over time, particularly during disease exacerbation.

114 **2. Materials and Methods**

115 **2.1 Study Participants**

116 Potential ME/CFS study participants were recruited to the UK ME/CFS Biobank (UKMEB)
117 [21] through the UK National Health Service or referred via patient support groups with ME/CFS.
118 They were required to have a confirmed medical diagnosis of ME/CFS and were re-assessed by
119 clinical research staff to ensure compliance with the Canadian Consensus [22] and/or CDC-1994
120 (“Fukuda”) [1] criteria, which were the study case definitions. Non-fatigued HC participants were
121 recruited as friends or family of people with ME/CFS or by advertisement in Higher Education
122 Institutions and GP practices. Participants were aged between 18 and 60 years and provided written
123 informed consent. Exclusion criteria included having taken anti-viral or immunomodulatory drugs
124 within the previous three months, chronic comorbid disease, a history of infectious disease such as

125 tuberculosis or hepatitis B or C, pregnancy and morbid obesity. Inclusion criteria included HHV
126 DNA detected in either plasma or PBMC (DNA positive) or HHV DNA not detected in either sample
127 (DNA negative (as described below, 5.2). Ethical approval was granted by the London School of
128 Hygiene & Tropical Medicine (LSHTM) Ethics Committee (Ref. 6123) and the National Research
129 Ethics Service (NRES) London-Bloomsbury Research Ethics Committee (REC ref. 11/10/1760,
130 IRAS ID:77765). Peripheral Blood Mononuclear Cells (PBMC) and plasma samples were
131 cryopreserved and stored from all UKMEB participants [21] and accessed for this study.

132 **2.2 Longitudinal Analysis**

133 Selected participants from the UKMEB cohort provided further written informed consent for
134 this longitudinal study. Participants were sent GeneFiX™ Saliva 2ml DNA Collection tubes
135 containing DNA stabilisation buffer and asked to return filled saliva tubes by post monthly for six
136 months as well as on the first, third and fifth day of any disease exacerbation episode including acute
137 illness or significant worsening of ME/CFS symptoms.

138 Clinical symptom assessment forms (Supplementary Figure 1), containing 58 questions with
139 graded answers, were completed and returned at the same time as each saliva sample. From these
140 data, symptom subgroup scores were developed, for immune, neuroendocrine, autonomic,
141 neurocognition, pain, sleep, and post-exertional related symptoms; the Canadian Consensus Criteria
142 assesses these domains for ME/CFS diagnosis [22]. The scores ranging from “0” to “100” represent
143 a weighted average of the reported symptoms on each domain, which are reported as “absent, mild,
144 moderate, or severe”.

145 **2.3 DNA extraction and Digital Droplet PCR**

146 DNA was extracted from stored plasma samples using the QIAamp MinElute Virus Spin Kit
147 (Qiagen), and from PBMC and saliva using the QIAamp DNA Mini Kit (Qiagen), according to the
148 manufacturer’s instructions. Each DNA extraction run included a seronegative control sample and a
149 Clinical Virology Multiplex I (National Institute for Biological Standards and Control (NIBSC))
150 positive extraction control: this comprised Adenovirus serotype 2, BK virus, CMV, EBV, HSV-1,
151 HSV-2, HHV-6A, HHV-6B, JC virus, Parvo B19 virus and VZV.

152 For assay development and to generate standard curves, titrated commercial quantitated DNA
153 was used: HSV-1, HSV-2, VZV & HHV-8 were purchased from Vircell (Granada, Spain), HHV-6A,
154 HHV-6B and HHV-7 were from ABI (Advanced Biotechnologies Inc, MD, USA) while EBV and
155 CMV were from the National Institute for Biological Standards and Control (NIBSC).

156 Each 20µl ddPCR reaction mix contained 10 µl ddPCR™ Supermix for Probes (Bio-Rad
157 Laboratories, Hercules, USA), 9 µl of template DNA, 1 µl of 20X primer and probe mix at a final
158 concentration 900 nM (for primer) and at 250 nM (for probe). Positive (commercial viral DNA) and
159 negative (water) controls were included in every ddPCR run. Primer and probe sequences are shown
160 in Supplementary Table 1, and were obtained from publications [23-28]. The reaction mix was
161 partitioned in oil-in-water with 70 µl of droplet generator oil using a QX-100 droplet generator (Bio-
162 Rad). The generated droplets (around 40 µl) were transferred to ddPCR™ 96-Well Plates (Bio-Rad)
163 using a multichannel pipette and covered with a pierceable PCR plate seal using a PX1™ PCR Plate
164 Sealer (Bio-rad). PCR amplification was performed with the following thermal cycling: 95 °C for 10
165 min, 40 cycles consisting of 94 °C for 30 sec (denaturation) and 60 °C for 1 min (extension),
166 followed by 98°C for 10 min and holding at 12 °C. After that, droplets (positive and negative) were
167 analysed using a QX100 droplet reader (Bio-rad) and the target DNA concentration was calculated

168 and presented as copies/ μ l in the reaction mixture using QuantaSoft software (Bio-Rad). The ddPCR
169 result was determined as positive when the DNA samples showed at least three positive droplets
170 from 10,000 to 15,000 droplets, according to the manufacturer's recommendation.

171 **2.4 Herpes virus serology**

172 Commercial ELISA kits were used to measure plasma concentrations of IgG to HSV-1, HSV
173 2, VZV, HCMV, EBV viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA 1) (from
174 Demeditec Diagnostics (Kiel, Germany)) and HHV-6 (from VIDIA (Vestec, Czech republic)): these
175 data have been reported previously [18], and are included here for comparison. The antibody
176 concentrations were calculated from standard curves. For qualitative evaluation of IgG antibodies to
177 HSV-1, HSV-2, VZV, CMV, EBV VCA, EBV, EBNA-1, the concentration was interpreted as:
178 concentration \leq 8 U/ml = negative, concentration \geq 12 U/ml = positive, and concentration between 8
179 and 12 U/ml = equivocal. For qualitative evaluation of IgG antibodies to HHV-6, concentration \leq
180 10.5 U/ml was considered negative, while concentration \geq 12.5 U/ml was considered positive and
181 concentration between 10.5 and 12.5 was considered equivocal.

182 **2.5 Data analysis**

183 Statistical analysis was conducted using GraphPad Prism 8.4.2 (GraphPad Software, San
184 Diego, CA). Continuous variables (viral loads, viral persistency and symptom scores) were described
185 using median and interquartile ranges (IQR) values or min to max as indicated. Mann-Whitney test
186 was used for viral load comparison of each HHV between clinical groups. The frequencies of HHV
187 were compared using the chi-square test. For correlation analysis between HHV viral load and
188 numerical clinical symptom scores or IgG titre from serological tests, the Spearman's correlation was
189 utilised. Differences where $P < 0.05$ are deemed significant, and in graphs * indicates $P < 0.05$, ** $P <$
190 0.01, *** $P < 0.001$.

191

192 **3 Results**

193 **3.1 Development of sensitive and specific ddPCR assays for human herpes viruses**

194 For each of the nine members of the human herpes family of viruses, ddPCR assays were
195 designed to run in duplex using specific primers and probes which were coupled to either FAM or
196 HEX reporter labels (Supplementary Table 1). Examples of single and duplex ddPCR assays for
197 HHV-6A and HHV-6B are shown in Figure 1A, with different proportions of positive and negative
198 droplets reflecting the starting concentration of commercial DNA. In duplex assays spiked with both
199 HHV-6A and HHV-6B DNA, the majority of \sim 15,000 droplets measured were PCR-negative for
200 both viruses, with substantial positivity observed for each individual virus but very few droplets
201 deemed to have dual positivity (Figure 1B), as expected. Reproducible precise standard curves were
202 obtained for each of the human herpes viruses (Figure 1C). Of note, the viral DNA copy number
203 detected by ddPCR for HHV-7 and VZV was lower than the commercial DNA quantity description, :
204 over-estimates of DNA concentration by absorbance spectrophotometry are common [29] .

205 **3.2 Study participant selection: detection of human herpes virus DNA in plasma and PBMC**

206 The aim of the longitudinal clinical study was to test whether the concentration of HHV DNA
207 in saliva reflected disease severity: in order to achieve this, we needed to identify potential
208 participants who had previously been exposed to HHVs (Figure 2). Previously [16], concentrations of

209 IgG antibodies against HSV-1, HSV-2, VZV, EBV, CMV and HHV-6 in plasma samples from 132
210 people with ME/CFS, 76 HC participants and 27 people with multiple sclerosis (MS) in the UKMEB
211 were measured by ELISA. Serum samples (189) with high IgG titre to CMV (≥ 90 U/ml) or EBV (\geq
212 150 U/ml for VCA or ≥ 90 U/ml for EBNA), or that were seropositive to \geq five out of six HHVs
213 measured, were screened by ddPCR to detect potential active (lytic) replication of any of the nine
214 HHVs. HHV DNA was rarely detected, with HSV-2, HHV-6A and HHV-6B detected in plasma
215 from one or two subjects and the remaining HHVs always negative (Table 1). We therefore screened
216 PBMC samples, which were available from 76 potential participants; EBV was detected in 8
217 subjects, CMV in 1 subject and HHV-7 in 25 subjects (Table 1), probably reflecting latent infection.
218 A single HHV DNA was detected in most cases of DNA positivity, whereas co-detection of HHVs
219 occurred in three individuals (1 HC: CMV & HHV-7; 2 ME/CFS_SA: EBV & HHV-7) (not shown).
220 Correlations between plasma IgG concentration and viral DNA concentration were weak due to low
221 DNA positivity rates (data not shown). The participant characteristics are shown in Supplementary
222 Table 2.

223 **3.3 Longitudinal study: clinical analysis of HHVs in saliva from people living with ME/CFS**

224 Candidates were selected for invitation to participate in the longitudinal study of saliva HHV
225 (Figure 2) if any HHV DNA was detected in either plasma or PBMC (DNA positive) or if HHV
226 DNA was not detected in either sample (DNA negative); all invited participants were seropositive for
227 all six HHVs tested. MS patients, who also have samples stored in the UK ME/CFS Biobank, were
228 not included in the longitudinal study due to low HHV DNA positivity in plasma and PBMC. A total
229 of 70 candidates were invited to participate in the study, of whom 46 were enrolled; their blood DNA
230 results reflected those of the group as a whole (Supplementary Table 2). Participants were requested
231 to post a saliva sample and a completed patient questionnaire (Supplementary Figure 1) to LSHTM
232 monthly for 6 months, and on the first, third and fifth day of any disease exacerbation episode
233 including acute illness or significant worsening of ME/CFS symptoms. From December 2017 to June
234 2018, 276 saliva samples were collected. The monthly sampling return rate was 92.7 %, 83.3 %, 97.9
235 % in HC, ME/CFS_MM (mild/moderate) and ME/CFS_SA (severely affected) groups respectively.
236 Additionally, one ME/CFS_MM and six ME/CFS_SA participants sent samples during episodes of
237 acute illness/worsening of symptoms: one ME/CFS_SA sent samples for two episodes (Figure 2).

238 **3.4 HHV prevalence and persistence over time in saliva from people with ME/CFS**

239 The concentration of DNA for each of the nine HHVs was measured in saliva samples from
240 ME/CFS patients (14 MM cases; 16 SA cases) and 16 HCs by ddPCR and the prevalence and
241 shedding pattern of HHVs investigated over time. Throughout the study time course, HSV-1, EBV,
242 HHV-6B and HHV-7 were detected in at least some participants, whereas the remaining HHVs were
243 undetectable throughout. Most saliva samples contained one, two or three HHVs. At the start of the
244 study (month 1), HHV-7 was the most prevalent HHV in saliva of all participants, whereas HSV-1
245 was detected from only 1 participant in each group (Figure 3A) and the prevalence of EBV and
246 HHV-6B differed between the groups (EBV: 56% (9/16) in HC, 29% (4/14) in ME/CFS_MM, 38%
247 (6/16) in ME/CFS_SA; HHV-6B: 25% (4/16) in HC, 29% (4/14) in ME/CFS_MM, 56% (9/16) in
248 ME/CFS_SA). HHV prevalence remained largely unchanged throughout the 6 months of follow up
249 with HHV-6B being the only virus to differ in prevalence between the groups, being borderline
250 significantly more highly prevalent in severely affected ME/CFS patients than in healthy controls
251 (Supplementary Table 3).

252 To investigate viral persistence, the proportion of samples from each participant that were
253 HHV-positive over the time course was determined (Figure 3B). HHV-7 was consistently detected in

254 all samples from the majority of participants throughout the 6 months (median for all 3 groups =
255 100%), whereas HSV-1, EBV and HHV-6B were only intermittently detected. HHV-6B was detected
256 significantly more frequently in the ME/CFS_SA participants (median: 33.3 %, IQR: 16.7-75 %),
257 than in HC (median: 8.33 %, IQR: 0-41.7 %; $p = 0.049$), but not in ME/CFS_MM participants
258 (median: 22.5 %, IQR: 0-70.8 %; $p = 0.28$). In contrast, there was no significant difference in the
259 frequency of detection of EBV or HSV-1 in HC compared to people with ME/CFS (Figure 3B).

260 **3.5 HHV DNA viral concentration in saliva in people living with ME/CFS**

261 The absolute HHV viral DNA concentration load in participants with ME/CFS was compared
262 with that in HC for the four detectable HHVs across the 6-month sampling time frame (Figure 3C-F).
263 There were no significant differences in absolute viral DNA load for HSV (Figure 3C) or EBV
264 (Figure 3D) between clinical groups. HHV-6B viral DNA concentrations were on average 6.2-fold
265 higher in ME/CFS_SA patients than in HC: the differences were significant at months 1, 3 and 5,
266 with a trend towards higher viral load across all time points (Figure 3E). There was a trend towards
267 higher HHV-6B DNA concentration in ME/CFS-MM participants than HC, with borderline
268 significance at months 3 and 5. Finally, HHV-7 viral loads were significantly higher in
269 ME/CFS_MM (at months 1,3,4 and 5) and ME/CFS_SA patients (at month 6) compared to HCs, with
270 a trend towards higher loads across all timepoints for both ME/CFS_MM and ME/CFS_SA groups,
271 with an average 4.1-fold increase in ME/CFS-MM and 3.0-fold increase in ME/CFS_SA compared
272 to HCs across the months (Figure 3F).

273 The Spearman correlation between plasma IgG concentration (in biobanked samples) and
274 salivary HHV viral DNA load for each participant was analysed for EBV and HHV-6
275 (Supplementary Figure 2). There was no significant correlation between EBV viral load and either
276 EBNA or VCA antibody concentration in people with ME/CFS or HC. Although there was a
277 significant negative correlation between anti HHV-6 IgG concentration and salivary HHV-6B DNA
278 concentration in the HC group, this was largely driven by one individual and no correlation was seen
279 in the ME/CFS participants.

280 There was no difference in salivary HHV viral load between participants who had been
281 deemed as HHV DNA-positive or DNA-negative in the initial plasma/PBMC ddPCR screening assay
282 (Table 2) although, among the HCs, those who were plasma/PBMC HHV DNA-positive were
283 significantly younger than those who were plasma/PBMC HHV DNA negative (Table 2). One HC in
284 whom HHV-6B was detected in plasma had very high concentrations of HHV-6B DNA in saliva but
285 this was an outlier and may reflect a recent infection (Supplementary Table 4). All people living with
286 ME/CFS in whom HHV-7 was detected in PBMC also had high concentrations of salivary HHV-7
287 DNA (Table 2).

288 When stratifying participants by age, the salivary HHV-6B DNA concentration was
289 significantly higher in younger (< 40 years) than older participants in the HC and ME/CFS_MM
290 groups but not the ME/CFS_SA group (Supplementary Table 5) but there were no significant
291 differences in HSV-1, EBV or HHV-7 DNA concentrations between age groups.

292 **3.6 Salivary HHV viral DNA concentration through time and during acute illness episodes in** 293 **people with ME/CFS**

294 Salivary DNA concentrations of HSV-1, EBV, HHV-6B and HHV-7 varied over time in
295 individual participants (Figure 4). Concentrations of HSV-1 and EBV DNA fluctuated month by
296 month in the majority of infected individuals with no obvious differences between clinical groups,

297 whereas there was less fluctuation in HHV-6B and HHV-7 DNA concentrations, with more
298 participants with ME/CFS than HC exhibiting persistently higher viral loads (Figure 4A).

299 There was no discernible pattern of changing HHV DNA concentrations during periods of
300 worsening disease symptoms in the seven ME/CFS participants (one MM case and 6 SA, one of
301 whom had two episodes of worsening symptoms) who had an acute illness or worsening of disease
302 symptoms (Figure 4B): rather there was fluctuation in detection of all four viruses during these
303 episodes, with both increases and decreases in viral load during exacerbated disease (Figure 4B and
304 Supplementary Figure 3).

305 **3.7 HHV co-infections in people with ME/CFS over time**

306 We investigated changes in detection of viral DNA from co-infecting HHV viruses over time
307 in individual study participants (Supplementary Figure 4 and Supplementary Table 6). At all time
308 points, HHV-7 was more frequently detected as the only HHV present in saliva than any other HHV;
309 HHV-7 together with HHV-6B, and HHV-7 together with EBV, as dual combinations of HHV
310 DNAs, and the triple combination of HHV-7 together with HHV-6B and EBV, were also frequently
311 observed (Supplementary Figure 4A). The quadruple combination (HHV-7 with HHV-6B, EBV and
312 HSV-1) and other HHV combinations as dual or triple infections were detected only rarely
313 (Supplementary Table 6). The HHV-7 with HHV-6B combination was significantly more frequently
314 found in ME/CFS_SA than in HC (chi square $p < 0.05$ at months 1 and 5), in accordance with the
315 higher frequency of HHV-6B DNA detection in severely affected ME/CFA patients. Dual detection
316 of HHV-7 with EBV was more frequent in ME/CFS_MM than in ME/CFS_SA participants, with
317 significant differences ($p < 0.05$) at months 2 and 4 and a trend in the other months.

318 People severely affected with ME/CFS could be broadly and evenly separated into two
319 subgroups, dependent on how their combinations of salivary HHV DNA changed over time. People
320 with pattern 1 showed varying combinations of one to four HHVs being detected over the 6-month
321 time course, whereas people with pattern 2 showed relatively simpler and more stable HHV
322 positivity consisting of one to two HHVs detectable (Supplementary Figure 4B). The majority of
323 people with mild/moderate ME/CFS symptoms (7/10) had the more stable HHV repertoire pattern
324 with only three ME/CFS_MM participants fitting the fluctuating repertoire pattern (data not shown).

325 **3.8 Correlation of ME/CFS symptoms with each other and with viral load**

326 To evaluate any association between disease symptoms and salivary detection of HHV DNA,
327 the numerically graded responses to the clinical questions collected together with each saliva sample
328 were categorised into seven domains (PEM, pain, sleep dysfunction, neurocognition, autonomic
329 nervous system, neuroendocrine system or immune system) to yield seven “symptom scores” for
330 each sample. First, we compared symptom scores by group (Figure 5A). HC individuals had low
331 scores across all symptom domains. People severely affected with ME/CFS had significantly higher
332 PEM scores ($p = 0.003$) and a tendency towards greater autonomic dysfunction than the
333 ME/CFS_MM group, whereas other symptoms did not differ significantly between the two groups.
334 We then examined the Spearman correlation of the symptom scores with each other: for all people
335 with ME/CFS (i.e. ME/CFS_MM and ME/CFS_SA combined: $n = 30$), all symptom scores
336 significantly correlated with each other (median of all $r = 0.508$, $p < 0.01$) (Figure 5B) and symptom
337 scores were significantly ($p = 0.0007$) more highly correlated among patients who were
338 mildly/moderately affected by ME/CFS than among those severely affected with ME/CFS (MM,
339 median of $r = 0.604$; SA, median of $r = 0.385$, all $p < 0.05$ for ME/CFS_MM group comparisons,
340 $p < 0.05$ for ME/CFS_SA group except Sleep dysfunction vs PEM $p = 0.108$ and vs Pain $p = 0.238$)

341 (Supplementary Figure 5). Of the seven symptom domain scores, autonomic symptoms were highly
342 correlated with neurocognition symptoms ($r = 0.70$) among all people with ME/CFS, and these two
343 symptom domain scores were moderately correlated with other symptom scores (autonomic
344 symptoms vs all others, median $r = 0.586$; neurocognition symptoms vs all others, median $r = 0.582$).
345 In contrast, sleep dysfunction symptoms were only weakly correlated with other symptoms scores
346 (median $r = 0.348$), except that among people severely affected with ME/CFS sleep dysfunction was
347 highly correlated with neuroendocrine' symptoms ($r = 0.62$). Finally pain symptoms were highly
348 correlated with neurocognition, autonomic and immune related symptoms ($r = 0.66, 0.66, 0.60$,
349 respectively) in people severely affected with ME/CFS.

350 We investigated the correlation between salivary HHV DNA concentration and symptom
351 scores across the 6 months of the study in people with ME/CFS (Supplementary Figure 5A-C) and
352 healthy controls; overall, the extent of correlation was weak. Among people severely affected with
353 ME/CFS, there were weak correlations between EBV DNA concentration and three symptom scores
354 (pain, neurocognition and autonomic: $r = 0.25, 0.23, 0.29$ respectively, all $p < 0.05$), between HSV-1
355 DNA concentration and autonomic symptoms ($r = 0.24, p < 0.05$), and between HHV-7 DNA
356 concentration and pain symptoms ($r = 0.25, p < 0.05$) and autonomic symptoms ($r = 0.24, p < 0.05$).
357 EBV DNA concentration correlated with HSV-1 DNA concentration in people severely affected with
358 ME/CFS ($r = 0.27, p < 0.01$), whereas HHV-6B correlated with HHV-7 ($r = 0.22, p < 0.05$)
359 (Supplementary Figure 5B). There were no significant correlations between salivary HHV DNA
360 concentration and symptom scores among people mildly/moderately affected with ME/CFS. This
361 group showed only weak negative correlation between EBV and HHV-6B salivary DNA
362 concentrations ($r = -0.25, p < 0.05$). Among the HC there were weak but statistically significant
363 correlations between detectable HHV-6B DNA in saliva and neuroendocrine symptoms ($r = 0.21, p <$
364 0.05) and between HSV-1 DNA concentration and both autonomic and immunological symptoms (r
365 $= 0.36, 0.22$, respectively, all $p < 0.05$). This group also showed correlation between EBV or HHV-
366 6B and HHV-7 salivary DNA concentrations ($r = 0.28, 0.22$, respectively, all $p < 0.05$).

367 We next investigated the correlation between salivary HHV DNA concentration and symptom
368 scores in the two subgroups of severely affected ME/CFS patients (pattern 1 and pattern 2,
369 Supplementary Figure 4B) (Figure 6, Supplementary Table 7). In the pattern 1 ME/CFS_SA group
370 (fluctuating levels of HHV DNA in saliva) there were strong and highly significant associations
371 between HHV-6B DNA concentration and six symptom domain scores (sleep dysfunction, pain,
372 neurocognition, autonomic, neuroendocrine and immune, $r = 0.47, 0.52, 0.65, 0.50, 0.46, 0.41$,
373 respectively, all $p \leq 0.01$). Three of these symptom domains were also correlated with HHV-7 DNA
374 concentration (pain, neurocognition and autonomic, $r = 0.49, 0.44, 0.47$ respectively, all $p = 0.002$ or
375 < 0.001). In contrast, in the pattern 2 ME/CFS_SA group (stable HHV DNA in saliva), HHV-6B
376 DNA concentration was negatively correlated with pain, neurocognition and neuroendocrine scores (r
377 $= -0.59, -0.43, -0.42$, respectively, all $p < 0.01$) whereas EBV DNA concentration was positively
378 associated with pain, neurocognition and autonomic symptoms ($r = 0.48, 0.40, 0.39$, respectively, $p =$
379 $0.001, 0.008, 0.010$ respectively). Moreover, neuroendocrine and immune system scores were
380 significantly higher in the pattern 1 group than the pattern 2 ($p < 0.01$) (data not shown). Finally,
381 when people with ME/CFS had an acute illness episode, during their sick days, the HHV-6B DNA
382 concentrations were positively correlated with sleep dysfunction and HHV-7 DNA concentration (r
383 $= 0.454, p < 0.05, r = 0.548, p < 0.01$ respectively; Supplementary Table 7). PEM and Pain were
384 negatively correlated with HHV-6B, $r = -0.647, p < 0.01, r = -0.426, p < 0.05$ respectively).
385 Interestingly, in all seven patients reporting an acute illness or worsening of symptoms, participants,
386 autonomic symptoms were markedly increased whereas neuroendocrine symptoms were decreased
387 (Supplementary Figure 6).

388

389 **4 Discussion**

390 Using duplex droplet digital PCR, we have analysed the prevalence and DNA load of human
391 herpes viruses in the saliva of ME/CFS patients and looked for associations with severity of
392 symptoms over time. In summary, HHV-7 was the most frequently detected HHV in saliva and
393 salivary HHV-7 DNA concentrations were significantly higher in people with ME/CFS than in
394 healthy controls; HHV-6B was more frequently detected, and with significantly higher viral loads, in
395 people severely affected with ME/CFS than in healthy controls and those with mild/moderate
396 ME/CFS, such that severely affected ME/CFS patients were more likely than other groups to be
397 HHV-6B/HHV-7 double-positive; and HHV-6B and HHV-7 viral loads correlated with disease
398 severity in a subgroup of people severely affected with ME/CFS whose salivary HHV repertoire
399 fluctuated over the 6 months of the study, suggesting that HHV-6B and HHV-7 may trigger
400 ME/CFS symptoms or be reactivated in concert with worsening symptoms. Importantly, although
401 HSV-1 and EBV were detected in some saliva samples, there were no consistent or statistically
402 significant differences in HSV-1 and EBV reactivation between people with ME/CFS and healthy
403 controls.

404 These findings are consistent with, and extend, previous data linking EBV, HHV-6 and HHV-7
405 infection and reactivation to the clinical course of ME/CFS (reviewed in [30]). Frequent HHV-6
406 and/or HHV7 infection or reactivation has been reported in chronic fatigue syndrome patients [31,
407 32], [33], [34] and has been linked to decreased cellular immune responses [31] and to ME/CFS
408 symptoms including PEM and lymphadenopathy [32]. Moreover, Chu et al [35] reported that one
409 third of patients had a documented acute HHV or B19 virus infection related to herpes viruses and
410 B19 virus associated with ME/CFS onset.

411 Saliva is a key transmission route for HHVs as the salivary gland is a particularly permissive
412 site for HHV replication. We detected HSV-1, EBV, HHV-6 and HHV-7 DNA in saliva samples,
413 either singly or in combinations of up to 4 HHVs, consistent with previous studies [36-39]; HHV-7
414 has been reported to be almost universally detected in saliva [40]. The prevalence of HSV-1, EBV
415 and HHV-7 in our healthy controls was broadly similar to a previous report Miller et al [39] but the
416 prevalence of HHV-6B (25%) was markedly lower than the 93.5% prevalence of HHV-6 reported
417 previously; this difference may reflect the detection target (HHV-6B rather than the whole HHV-6
418 genome), methodology or genuine population differences. Furthermore, in all but one of our study
419 participants, detection of HHV DNA in saliva (evidence of virus reactivation and shedding) was
420 highly correlated with detection of viral DNA in previously collected (baseline) samples of PBMCs
421 (where the virus may be latent) or plasma, indicating that these are longstanding, persistent infections
422 rather than acute/recent infections. However, in one of our healthy control participants very high
423 plasma and salivary concentrations of HHV-6B DNA were positively correlated with immune-related
424 and autonomic symptoms, suggestive of a primary lytic infection in this individual. Future studies
425 could investigate correlations between viral loads in plasma, PBMCs and saliva at the same sampling
426 time point.

427 Herpes viruses maintain latent infections at different anatomical sites. HHV-6 and HHV-7
428 remain dormant inside leukocytes, mainly T cells, and their genomes integrate into host
429 chromosomal telomeres providing a mechanism for viral reactivation via the release of telomeric
430 circular DNA following T cell activation in response to a heterologous infection [41, 42].
431 Furthermore, HHV-7 can reactivate HHV-6A/B while HHV-6 has been found to activate Epstein-

432 Barr virus from latency [43-45]. HHV-6 and HHV-7 latency within leukocytes leads to wide-ranging
433 impacts on the immune system [4] including changes in host cell transcriptomes and metabolism
434 [46], down-regulation of antigen presentation and modulation of cytokines and chemokines [47, 48],
435 impairment of NK cell function [49], and enhancement of proinflammatory cytokine and chemokine
436 responses to Toll-like receptor 9 signalling [50]. HHV-6 reactivation in ME/CFS patients can also
437 lead to mitochondrial fragmentation and severely compromised energy metabolism [51]; this may be
438 linked to reported interactions between the HHV-6B U95 early viral protein and the mitochondrial
439 GRIM-19 protein [52] that results in reduced mitochondrial membrane potential and pronounced
440 mitochondrial impairment. It has also been postulated that persistent HHV infection/reactivation
441 during which effector T cells are controlled by regulatory T cells may also lead to ME/CFS
442 symptoms [53]. The weak but statistically significant correlations observed here between reactivation
443 of HHV-6, HHV-7 and EBV, and the correlations between HHV viral loads and severity of disease
444 symptoms in ME/CFS patients, may thus reflect T cell activation either by one of these HHVs or by
445 another infectious agent; and/or HHV-induced dysfunction of various cells of the immune system;
446 and/or direct or indirect effects of HHVs on mitochondrial function. Whilst we did not observe any
447 significant association between HHV reactivation and episodes of disease exacerbation, this may be
448 due to the low number of acute disease episodes in our study, and to the marked heterogeneity of
449 ME/CFS patients. Larger and longer studies will be needed to properly address this hypothesis and
450 identify potential triggers.

451 In summary, This pilot study demonstrates that it is possible to recruit people living with
452 ME/CFS and to collect biologically relevant samples, longitudinally, even during periods of disease
453 exacerbation, opening up the prospect of conducting large-scale studies to investigate the role of
454 human herpes viruses in ME/CFS pathogenesis. Our data indicate that HHV6B and HHV7 are
455 associated with ME/CFS disease severity. Herpes virus reactivation might either be a cause or effect
456 of ME/CFS manifestation: either a disturbance in immune system function caused by ME/CFS
457 disease development enables a persistent HHV viral infection to become reactivated, or the
458 reactivation of the virus might be the precipitating factor for the worsening of ME/CFS symptoms.
459 Many factors, such as co-infection, long-term stress, immunosuppressive therapy and autoimmune
460 disease can lead to HHV reactivation, which would fit with heterogeneity seen in ME/CFS cohorts.
461 Long-term, large-scale studies are warranted to determine cause versus effect for the role of HHVs in
462 ME/CFS.

463 **5 Conflict of Interest**

464 The authors declare that the research was conducted in the absence of any commercial or financial
465 relationships that could be construed as a potential conflict of interest.

466 **6 Author Contributions**

467 ER, CR, EL, LN devised the study and obtained funding, EL, CK, JN, SO conducted the clinical
468 assessments and collected samples, JL, CR, ER, JC designed and implemented the laboratory studies
469 JL, JC, LP, analysed data or contributed to interpretation. JL, JC, EL, CK, LP, ER, wrote the
470 manuscript. All authors revised the manuscript critically for important intellectual content and
471 approved the final version.

472 **7 Funding**

473 This work was supported by funding from National Institute of Allergy and Infectious Diseases
474 (NIAID) of the National Institutes of Health (NIH) under Award Number R21AI121759.

475 **8 Acknowledgments**

476 We thank all the study participants for their time and energy and for donating their regular saliva
477 samples to this study, and their blood to the UK ME/CFS Biobank. We thank Judith Breuer for
478 virology advice, Robert Butcher, Martin Goodier and Zakaya Nasser Al Rasbi for advice on ddPCR
479 assay design, and Kenneth Laing for access to the droplet reader.

480 **9 References**

- 481 1. Fukuda, K., et al., *The chronic fatigue syndrome: a comprehensive approach to its definition*
482 *and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med, 1994.*
483 **121**(12): p. 953-9.
- 484 2. Kingdon, C.C., et al., *Functional Status and Well-Being in People with Myalgic*
485 *Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis*
486 *and Healthy Controls. Pharmacoecoon Open, 2018.*
- 487 3. Estevez-Lopez, F., et al., *Systematic Review of the Epidemiological Burden of Myalgic*
488 *Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and*
489 *EUROMENE Research Recommendations for Epidemiology. J Clin Med, 2020. 9*(5).
- 490 4. Rasa, S., et al., *Chronic viral infections in myalgic encephalomyelitis/chronic fatigue*
491 *syndrome (ME/CFS). J Transl Med, 2018. 16*(1): p. 268.
- 492 5. Patrick, D.M., et al., *Lyme Disease Diagnosed by Alternative Methods: A Phenotype Similar*
493 *to That of Chronic Fatigue Syndrome. Clin Infect Dis, 2015. 61*(7): p. 1084-91.
- 494 6. Morroy, G., et al., *Fatigue following Acute Q-Fever: A Systematic Literature Review. PLoS*
495 *One, 2016. 11*(5): p. e0155884.
- 496 7. Holmes, G.P., et al., *A cluster of patients with a chronic mononucleosis-like syndrome. Is*
497 *Epstein-Barr virus the cause? JAMA, 1987. 257*(17): p. 2297-302.
- 498 8. Straus, S.E., et al., *Persisting illness and fatigue in adults with evidence of Epstein-Barr virus*
499 *infection. Ann Intern Med, 1985. 102*(1): p. 7-16.
- 500 9. Cameron, B., et al., *Serological and virological investigation of the role of the herpesviruses*
501 *EBV, CMV and HHV-6 in post-infective fatigue syndrome. J Med Virol, 2010. 82*(10): p.
502 1684-8.
- 503 10. Levine, P.H., et al., *Clinical, epidemiologic, and virologic studies in four clusters of the*
504 *chronic fatigue syndrome. Arch Intern Med, 1992. 152*(8): p. 1611-6.
- 505 11. Lerner, A.M., et al., *IgM serum antibodies to human cytomegalovirus nonstructural gene*
506 *products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with*
507 *chronic fatigue syndrome. In Vivo, 2002. 16*(3): p. 153-9.
- 508 12. Shikova, E., et al., *Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections*
509 *in patients with myalgic small ie, Cyrillicncephalomyelitis/chronic fatigue syndrome. J Med*
510 *Virol, 2020.*
- 511 13. Caselli, E. and D. Di Luca, *Molecular biology and clinical associations of Roseoloviruses*
512 *human herpesvirus 6 and human herpesvirus 7. New Microbiol, 2007. 30*(3): p. 173-87.
- 513 14. Komaroff, A.L., *Chronic fatigue syndromes: relationship to chronic viral infections. J Virol*
514 *Methods, 1988. 21*(1-4): p. 3-10.

- 515 15. Patnaik, M., et al., *Prevalence of IgM antibodies to human herpesvirus 6 early antigen*
516 *(p41/38) in patients with chronic fatigue syndrome*. J Infect Dis, 1995. **172**(5): p. 1364-7.
- 517 16. Koelle, D.M., et al., *Markers of viral infection in monozygotic twins discordant for chronic*
518 *fatigue syndrome*. Clin Infect Dis, 2002. **35**(5): p. 518-25.
- 519 17. Wallace, H.L., 2nd, et al., *Human herpesviruses in chronic fatigue syndrome*. Clin Diagn Lab
520 Immunol, 1999. **6**(2): p. 216-23.
- 521 18. Cliff, J.M., et al., *Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue*
522 *Syndrome (ME/CFS)*. Front Immunol, 2019. **10**: p. 796.
- 523 19. Hindson, B.J., et al., *High-throughput droplet digital PCR system for absolute quantitation of*
524 *DNA copy number*. Anal Chem, 2011. **83**(22): p. 8604-10.
- 525 20. Nacul, L., et al., *How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)*
526 *Progresses: The Natural History of ME/CFS*. Front Neurol, 2020. **11**: p. 826.
- 527 21. Lacerda, E.M., et al., *The UK ME/CFS Biobank for biomedical research on Myalgic*
528 *Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis*. Open J
529 Biosour, 2017. **4**.
- 530 22. Carruthers B., et al., *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical*
531 *Working Case Definition, Diagnostic and Treatment Guidelines A Consensus Document*.
532 Journal of chronic fatigue syndrome, 2003. **11**(1): p. 7-115.
- 533 23. Weidmann, M., U. Meyer-Konig, and F.T. Hufert, *Rapid detection of herpes simplex virus*
534 *and varicella-zoster virus infections by real-time PCR*. J Clin Microbiol, 2003. **41**(4): p.
535 1565-8.
- 536 24. Sugita, S., et al., *Use of multiplex PCR and real-time PCR to detect human herpes virus*
537 *genome in ocular fluids of patients with uveitis*. Br J Ophthalmol, 2008. **92**(7): p. 928-32.
- 538 25. Lin, C.T., et al., *Human herpesvirus multiplex ddPCR detection in brain tissue from low- and*
539 *high-grade astrocytoma cases and controls*. Infect Agent Cancer, 2016. **11**: p. 32.
- 540 26. Sedlak, R.H., et al., *Detection of Human Herpesvirus 6B (HHV-6B) Reactivation in*
541 *Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A*
542 *by Droplet Digital PCR*. J Clin Microbiol, 2016. **54**(5): p. 1223-7.
- 543 27. Zerr, D.M., et al., *Sensitive method for detection of human herpesviruses 6 and 7 in saliva*
544 *collected in field studies*. J Clin Microbiol, 2000. **38**(5): p. 1981-3.
- 545 28. Stamey, F.R., et al., *Quantitative, fluorogenic probe PCR assay for detection of human*
546 *herpesvirus 8 DNA in clinical specimens*. J Clin Microbiol, 2001. **39**(10): p. 3537-40.
- 547 29. Beinhauerova, M., et al., *Utilization of Digital PCR in Quantity Verification of Plasmid*
548 *Standards Used in Quantitative PCR*. Frontiers in Molecular Biosciences, 2020. **7**.
- 549 30. Ablashi, D.V., *Viral studies of chronic fatigue syndrome*. Clin Infect Dis, 1994. **18 Suppl 1**:
550 p. S130-3.
- 551 31. Ablashi, D.V., et al., *Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic*
552 *fatigue syndrome (CFS) patients*. J Clin Virol, 2000. **16**(3): p. 179-91.
- 553 32. Chapenko, S., et al., *Association of active human herpesvirus-6, -7 and parvovirus b19*
554 *infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue*
555 *syndrome*. Adv Virol, 2012. **2012**: p. 205085.

- 556 33. Chapenko, S., et al., *Activation of human herpesviruses 6 and 7 in patients with chronic*
557 *fatigue syndrome*. J Clin Virol, 2006. **37 Suppl 1**: p. S47-51.
- 558 34. Blomberg, J., et al., *Antibodies to Human Herpesviruses in Myalgic*
559 *Encephalomyelitis/Chronic Fatigue Syndrome Patients*. Frontiers in Immunology, 2019. **10**.
- 560 35. Chu, L., et al., *Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue*
561 *Syndrome*. Front Pediatr, 2019. **7**: p. 12.
- 562 36. Aoki, R., et al., *Human herpesvirus 6 and 7 are biomarkers for fatigue, which distinguish*
563 *between physiological fatigue and pathological fatigue*. Biochem Biophys Res Commun,
564 2016. **478**(1): p. 424-430.
- 565 37. Ihira, M., et al., *Variation of human herpesvirus 7 shedding in saliva*. J Infect Dis, 2003.
566 **188**(9): p. 1352-4.
- 567 38. Matrajt, L., et al., *Virus and host-specific differences in oral human herpesvirus shedding*
568 *kinetics among Ugandan women and children*. Sci Rep, 2017. **7**(1): p. 13105.
- 569 39. Miller, C.S., et al., *Effect of prophylactic valacyclovir on the presence of human herpesvirus*
570 *DNA in saliva of healthy individuals after dental treatment*. J Clin Microbiol, 2005. **43**(5): p.
571 2173-80.
- 572 40. Wyatt, L.S. and N. Frenkel, *Human herpesvirus 7 is a constitutive inhabitant of adult human*
573 *saliva*. J Virol, 1992. **66**(5): p. 3206-9.
- 574 41. Prusty, B.K., et al., *Possible chromosomal and germline integration of human herpesvirus 7*.
575 J Gen Virol, 2017. **98**(2): p. 266-274.
- 576 42. Prusty, B.K., G. Krohne, and T. Rudel, *Reactivation of chromosomally integrated human*
577 *herpesvirus-6 by telomeric circle formation*. PLoS Genet, 2013. **9**(12): p. e1004033.
- 578 43. Katsafanas, G.C., et al., *In vitro activation of human herpesviruses 6 and 7 from latency*. Proc
579 Natl Acad Sci U S A, 1996. **93**(18): p. 9788-92.
- 580 44. De Bolle, L., L. Naesens, and E. De Clercq, *Update on human herpesvirus 6 biology, clinical*
581 *features, and therapy*. Clin Microbiol Rev, 2005. **18**(1): p. 217-45.
- 582 45. Hall, C.B., et al., *Characteristics and acquisition of human herpesvirus (HHV) 7 infections in*
583 *relation to infection with HHV-6*. J Infect Dis, 2006. **193**(8): p. 1063-9.
- 584 46. Wu, Z., et al., *Human herpesvirus 6A promotes glycolysis in infected T cells by activation of*
585 *mTOR signaling*. PLoS Pathog, 2020. **16**(6): p. e1008568.
- 586 47. Dagna, L., J.C. Pritchett, and P. Lusso, *Immunomodulation and immunosuppression by*
587 *human herpesvirus 6A and 6B*. Future Virol, 2013. **8**(3): p. 273-287.
- 588 48. Mirandola, P., et al., *Down-regulation of human leukocyte antigen class I and II and beta 2-*
589 *microglobulin expression in human herpesvirus-7-infected cells*. J Infect Dis, 2006. **193**(7): p.
590 917-26.
- 591 49. Rizzo, R., et al., *HHV-6A/6B Infection of NK Cells Modulates the Expression of miRNAs and*
592 *Transcription Factors Potentially Associated to Impaired NK Activity*. Front Microbiol, 2017.
593 **8**: p. 2143.
- 594 50. Bortolotti, D., et al., *DNA Sensors' Signaling in NK Cells During HHV-6A, HHV-6B and*
595 *HHV-7 Infection*. Front Microbiol, 2020. **11**: p. 226.

- 596 51. Schreiner, P., et al., *Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and*
597 *the Coordination of Antiviral and Metabolic Phenotypes in Myalgic*
598 *Encephalomyelitis/Chronic Fatigue Syndrome*. Immunohorizons, 2020. **4**(4): p. 201-215.
- 599 52. Yeo, W.M., Y. Isegawa, and V.T. Chow, *The U95 protein of human herpesvirus 6B interacts*
600 *with human GRIM-19: silencing of U95 expression reduces viral load and abrogates loss of*
601 *mitochondrial membrane potential*. J Virol, 2008. **82**(2): p. 1011-20.
- 602 53. Sepulveda, N., et al., *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-*
603 *Regulated Immune System Driven by an Interplay Between Regulatory T Cells and Chronic*
604 *Human Herpesvirus Infections*. Front Immunol, 2019. **10**: p. 2684.

605

606 **10 Data Availability Statement**

607 The raw data supporting the conclusions of this article will be made available by the authors, without
608 undue reservation.

609

610 **11 Tables**

611

612 Table 1. Human herpes virus DNA in plasma and PBMC with anti-HHV IgG concentration

ddPCR		HHV serology						Group of ddPCR positive samples (n=)	
		Positive		Negative		Border			
		number (n=)	IgG median (IU/ml)	number (n=)	IgG median (IU/ml)	number (n=)	IgG median (IU/ml)		
HSV-1									
PLASMA	Positive	0	-	0	-	0	-	-	
	Negative	115	131.00	62	4.60	12	10.19		
PBMC	Positive	0	-	0	-	0	-		
	Negative	34	115.70	40	2.34	2	9.91		
HSV-2									
PLASMA	Positive	0	-	1*	2.87	0	-		*MS (1)
	Negative	100	93.45	82	2.84	6	10.50		
PBMC	Positive	0	-	0	-	0	-		
	Negative	30	99.33	44	3.10	2	10.97		
VZV									
PLASMA	Positive	0	-	0	-	0	-	-	
	Negative	184	143.58	4	7.54	1	10.76		
PBMC	Positive	0	-	0	-	0	-		
	Negative	74	126.92	3	8.79	0	-		
EBV (anti VCA IgG)									
PLASMA	Positive	0	-	0	-	0	-		** HC (3), ME/CFS_MM (2), ME/CFS_SA (3)
	Negative	169	156.65	13	4.71	0	-		
PBMC	Positive	8**	120.26	0	-	0	-		
	Negative	58	120.65	8	2.60	2	8.71		
EBV (anti EBNA-1 IgG)									
PLASMA	Positive	0	-	0	-	0	-	*** HC (2), ME/CFS_MM (2), ME/CFS_SA (1) # HC (1), ME/CFS_SA (1) ~ ME/CFS_SA (1)	
	Negative	140	55.42	35	5.95	7	9.52		
PBMC	Positive	5***	47.93	2#	4.92	1~	8.58		
	Negative	50	50.56	13	5.68	5	11.25		
CMV									
PLASMA	Positive	0	-	0	-	0	-		∞ HC (1)
	Negative	94	110.81	85	3.73	3	8.38		
PBMC	Positive	0	-	1∞	2.76	0	-		
	Negative	24	85.445	48	4.15	3	8.86		
HHV-6									
PLASMA	Positive	1 ^l	100.33	0	-	0	-	^l HC (1) [§] HC (2) ⁺ HC (1)	
HHV-6A	Negative	180	59.15	6	6.475	2	11.85		
PLASMA	Positive	2 [§]	87.14	0	-	0	-		
HHV-6B	Negative	179	59.43	6	6.475	2	11.85		
PBMC	Positive	1 ⁺	100.33	0	-	0	-		
HHV-6A	Negative	71	42.44	4	5.16	0	-		
PBMC	Positive	0	-	0	-	0	-		
HHV-6B	Negative	72	43.74	4	5.16	0	-		
HHV-7 (No serology data) ^									
PLASMA	Positive	0							[¶] HC (7), ME/CFS_MM (9), ME/CFS_SA (9)
	Negative	182							
PBMC	Positive	25 [¶]							
	Negative	51							
HHV-8 (No serology data) ^									
PLASMA	Positive	0							
	Negative	182							
PBMC	Positive	0							

Negative 76

613 ^ There were no commercial ELISA kits available for HHV-7 and HHV-8.

614

615 **Table 2: HHV viral load in saliva of participants who were HHV DNA-positive or DNA-**
 616 **negative in the initial ddPCR screening assay of plasma and PBMC**

MONTH 1		N	Median Age (IQR)	p-value	Gender (n)	Median viral load (IQR, copies/ml saliva)			
DNA positivity in plasma / PBMC	HSV-1					EBV	HHV-6B	HHV-7	
HC	Negative	11	46 (37-51)	<0.05	F (8)/M (3)	0 (0-13,374)	3600 (0-13,374)	0	16,308 (682-34,600)
	Positive	5	32 (20.5-43.0)		F (5)	0 (0-19,017)	4500 (0-19,017)	0 (0-63700)	10500 (2,400-41,167)
ME/ CFS_ MM	Negative	12	42 (37.0-49.8)		F (12)	0 (0-15580)	0 (0-15580)	0 (0-805)	46,500 (8,192-65,350)
	Positive	2	47.5 (42.0-53.0)		F (2)	0 (0-60,150)	30075 (0-60,150)	0	43,653 (1,440-85,867)
ME/ CFS_ SA	Negative	11	49 (35-54)		F (7)/M (4)	0 (0-960)	0 (0-960)	0 (0-690)	11,400 (0-23183)
	Positive	5	35 (25-56)		F (5)	0 (0-24,354)	0 (0-24,354)	467.4 (0-2,517)	48,300 (18,396-75,600)

617

618

619 Figure Legends

620 **Figure 1: DNA concentration measured by ddPCR assays for the nine human herpes viruses.**

621 A) Example 1D dot plot data file for HHV-6A and HHV-6B ddPCR assays. The X-axes show
622 quantities of commercial viral DNA in different assay plate wells (E02, F02, G02 etc.). Assays were
623 run either singly or in duplex as shown. The Y-axes indicate the fluorescence intensity within each
624 PCR droplet, with the pink line indicating the threshold for positivity. B) Example representation of
625 2D dot plot displaying duplex ddPCR of HHV-6B (FAM labelled, channel 1) and HHV-6A (HEX
626 labelled, channel 2). C) Standard curves obtained for each of the nine human herpes viruses,
627 indicating the concentration of serial dilutions of commercial DNA on the X-axes, and the calculated
628 concentration of viral DNA from the ddPCR assay on the Y-axes.

629

630 **Figure 2: Flow diagram of participant recruitment and follow up in the longitudinal saliva**

631 **clinical study.** Serological test (n=235) and consecutive ddPCR assay in the plasma (n=189) and
632 PBMC (n=76) were performed for HHV screening purposes. In total, 46 participants were enrolled
633 into a 6-month longitudinal study to determine salivary HHV. Saliva samples (monthly and day 1,3
634 and 5 of an acute illness or worsening of disease episode in people with ME/CFS, n= 276) were then
635 analysed for HHV DNA concentration by ddPCR assay, with results compared with symptoms
636 scores. *30 participants were tested for both plasma and PBMC.

637

638 **Figure 3. Herpes virus DNA prevalence and concentration in saliva from people living with**

639 **ME/CFS, measured by ddPCR.** A) Percentage HHV prevalence in HC (n=16) and people with
640 mild/moderate ME/CFS (ME/CFS_MM: n=14) or severe symptoms (ME/CFS_SA: n=16) at month
641 1. B) Persistence of viral DNA positivity throughout 6 months. The persistency (%) was calculated
642 for each participant as the number of times HHV was detected divided by the total number of
643 samples collected over 6 months, multiplied by 100. HHV viral DNA concentration comparison
644 between HC and ME/CFS patients. Each monthly viral DNA concentration in saliva from
645 participants with mild/moderate (ME/CFS_MM) or severe (ME/CFS_SA) disease was compared to
646 HC across the 6 months for C) HSV-1, D) EBV, E) HHV-6B and F) HHV-7. Scatter dot plots show
647 the median and the interquartile range. P values < 0.1 (Mann-Whitney) are shown.

648

649 **Figure 4. Change in herpes virus DNA concentration in saliva in individual participants over**

650 **time.** A) The monthly viral load of HSV-1, EBV, HHV-6B and HHV-7 detected in saliva from
651 month 1 (Jan 2018) to month 6 (Jun 2018), measured by ddPCR assay, is shown for individual HC,
652 ME/CFS_MM and ME/CFS_SA study participants. B) The HHV viral load of HSV-1, EBV, HHV-
653 6B and HHV-7 in ME/CFS patients is shown on day 1, day 3 and day 5 of episodes when participants
654 experienced an acute illness or worsening of disease symptoms.




655


656 **Figure 5: Disease symptom and correlation in people living with ME/CFS and Healthy controls.**







657 A) Median score and IQR of seven ME/CFS symptom domains across 6 months in people with
658 mild/moderate (n=14) or severe ME/CFS (n=16) and HC (n=16), based on questionnaires completed
659 at the time of saliva sample collection by participants. B) Correlation matrix between seven ME/CFS
660 symptom domain scores in people with ME/CFS (n=30).





661 **Figure 6. Correlations of salivary HHV DNA concentration with disease symptoms scores.** A)
662 Correlation between monthly symptoms score and monthly HHV viral DNA concentration in people
663 with ME/CFS_SA (pattern 1, left panel; pattern 2, right panel). All participant's monthly HHV viral
664 DNA concentration and symptoms score data were included in the correlation analysis. Each symbol
665 represents an individual's monthly sample. Spearman's coefficient is denoted as r . The best-fit
666 regression line, 95% confidence interval (grey area) and prediction band (dotted line) are shown. B)
667 Correlation between symptom scores and EBV, HHV-6B and HHV7 DNA concentrations in saliva
668 samples from participants experiencing an exacerbation of symptoms.

669


A**B****C**








A







B







A

ME/CFS_SA_Pattern 1



ME/CFS_SA_Pattern 2

**B**